The effect of altering heart rate on ventricular function in patients with heart failure treated with h-blockers
|
|
- Jessica Burns
- 6 years ago
- Views:
Transcription
1 The effect of altering heart rate on ventricular function in patients with heart failure treated with h-blockers Simon D.R. Thackray, MRCP, a Justin M. Ghosh, MRCP, Graham A. Wright, PhD, b Klaus K.A. Witte, MRCP, Nikolay P. Nikitin, PhD, Gerald C. Kaye, MD, FRCP, Andrew L. Clark, MA, MD, FRCP, Ann Tweddel, MD, FRCP, and John G.F. Cleland, MD, FRCP, FESC, FACC Kingston-upon-Hull, United Kingdom Background h-blockers are effective for the treatment of heart failure, but their mechanism of action is unresolved. Heart rate reduction may be a central mechanism or a troublesome side effect. Methods A randomized, double-blind, parallel group study comparing chronic higher-rate (80 pulses per minute) with lower-rate (60 pulses per minute) pacing in pacemaker-dependent patients with symptomatic left ventricular (LV) systolic dysfunction, receiving h-blockers. Gated radionuclide ventriculography (RNVG) was performed at baseline and after at least 9 months. The primary outcome was change in LV volumes, as a marker of beneficial reverse remodeling, from baseline to follow-up. Results Forty-nine patients were randomized. Mean age was 74 F 6 years and with LV ejection fraction of 26% F 9% at baseline. During 14 F 13 months of follow-up, 21 patients (43%) died and 25 (51%) completed the study protocol: 12 in the higher-rate and 13 in the lower-rate group. Mean LV end-diastolic (higher rate +20 F 104 ml vs lower rate 65 F 92 ml, P =.03) and systolic (higher rate +29 F 83 ml vs lower rate 60 F 74 ml, P =.006) volumes increased with higher-rate versus lower-rate pacing, whereas LV ejection fraction declined (higher rate 4.2% F 4.4% vs lower rate +2.2% F 5.4%, P =.002). Conclusion Reversal of h-blocker induced bradycardia has deleterious effects on ventricular function, suggesting heart rate reduction is an important mediator of their effects. The prognosis of patients with pacemakers and heart failure is poor. (Am Heart J 2006;152:713.e92713.e13.) h-blockers reduce morbidity and mortality in patients with heart failure, 1 but the mechanisms mediating this effect are uncertain. It is likely that improvement in left ventricular (LV) function is an important factor. 2,3 However, the mechanism by which h-blockers improve LV function is also uncertain. Possible mechanisms include blockade of adrenergic receptors, leading to improved cardiac myocyte metabolism and a reduction in apoptosis, 4,5 a reduction in heart rate, 6,7 a reduction in atrial and ventricular arrhythmias, 8 or a reduction in myocardial ischemia and/or hibernation. 9,10 The data supporting the hypothesis that h-blockers exert their effects merely by slowing heart rate are From the a Department of Academic Cardiology, University of Hull, Castle Hill Hospital, Kingston-upon-Hull, United Kingdom, and b Department of Nuclear Medicine, Hull Royal Infirmary, Kingston-upon-Hull, United Kingdom. No conflicts of interest exist for any of the authors. This work is entirely supported by a grant from the British Heart Foundation. Submitted October 15, 2005; accepted July 13, Reprint requests: Simon D.R. Thackray, MRCP, Department of Academic Cardiology, University of Hull, Castle Hill Hospital, Cottingham, East Yorkshire, United Kingdom. simonthackray@hotmail.com /$ - see front matter n 2006, Published by Mosby, Inc. doi: /j.ahj inconclusive, and observational data are conflicting Even if the 2 phenomena are correlated, this does not prove cause and effect. Bradycardia could be a critically necessary mediator of the benefits of h-blockers or may just be an unwanted side effect. Prevention of bradycardia could enhance the benefits of h-blockade, for instance, by improving symptoms like breathlessness and fatigue or by allowing institution of therapy even in patients with low heart rates. Moreover, in patients with heart failure who have had a pacemaker implanted for conducting system disease, it is not known whether prevention of bradycardia would attenuate the benefits of h-blockade. Finally, if heart rate reduction is central to the effect of h-blockade, then nonadrenergic ratemodifying agents such as ivabradine 14 may become useful agents in treatment of chronic heart failure. Methods Setting The study was done in a regional tertiary referral cardiothoracic center serving a mixed urban/rural population of for the purposes of pacemaker implantation. Written informed consent was obtained from all patients. The local research ethics committee approved the study.
2 713.e10 Thackray et al. American Heart Journal October 2006 Table I. Baseline characteristics and response to different paced rates High rate (80 ppm 1 ) (n = 12) Low rate (60 ppm 1 ) (n = 13) P Age (y) 70 F 7 75 F 6 P =NS Carvedilol dose (mg) 25 F 7 26 F 7 P =NS Ischemic heart disease 10 (83%) 11 (85%) P = NS Months paced at entry 30 F F 34 P =NS Paced rate at entry 62 F F 2.7 P =NS Paced ventricular beats during study (% of total) 95% F 4% 92% F 7% P =NS Mean heart rate during study period 83 F 2 beat/min 1 64 F 3 beat/min 1 P b.001 Follow-up (m) 13.6 F F 2.7 P =NS DDD/VVI (R) (n) 6/6 7/6 P =NS SR/AF (n) 7/5 8/5 P =NS Baseline LVEF (%) 26.2 F F 8.9 P =NS Change in LVEF (%) 4.5 F F 5.4 P =.002 Baseline LVEDV 317 F 127 ml 349 F 123 ml P =NS Change in LVEDV +8 F 104 ml 65 F 92 ml P =.03 Baseline LVESV 235 F 119 ml 285 F 117 ml P =NS Change in LVESV +23 F 83 ml 61 F 74 ml P =.006 Improved LV function4 1 of 12 (8%) 7 of 13 (53%) P b.001 Data are presented as mean F 1 SD. 4Defined as reduced LVEDVs (ml) and improved LV ejection fraction from baseline to follow-up RNVG. Patient selection Patients with symptoms of heart failure and LV systolic dysfunction (LV ejection fraction on biplane echocardiography of b40%) were identified by screening consecutive patients attending a routine pacemaker follow-up clinic. 15 Other inclusion criteria were permanent pacing for N3 months, age N18 years, and symptoms compatible with heart failure present for N3 months. Exclusion criteria were a recent (b1 month) myocardial infarction or cardiac surgery, biventricular pacing devices, contraindications to h-blocker therapy, or inability to give informed consent. Interventions Patients were randomized either to lower-rate ventricular pacing, with pacing rate set at 60 ppm and any rate response algorithm set to low, or higher-rate ventricular pacing, with pacing rate set at 80 ppm with any rate response algorithm set to medium or high. Patients were randomized to 1 of 2 groups on a 1:1 basis using random number blocks. Patients with single-chamber VVI pacemakers and dual-chamber DDD pacemakers were randomized separately to achieve an equal ratio in each group. Patient assessment In addition to a medical history, New York Heart Association classification, and physical examination, patients had an electrocardiogram, blood tests for renal function and hemoglobin, and an echocardiogram. Patients were assessed clinically at 3-month intervals for at least 9 months. Duration of pacing, current pacing mode, indication for pacing, and rhythm at implant were recorded. Number of paced beats as a percentage of total was derived from the internal pacemaker histograms or from 24-hour Holter monitoring if not available from pacemaker telemetry. Chronic atrial fibrillation (AF) was defined, for the purposes of this study, as the presence of AF, diagnosed on serial 12-lead electrocardiograms. Patients not already treated with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, h-blockers, and spironolactone had treatment initiated and titrated to optimal doses. Carvedilol was the standard h-blocker used in our clinical practice. Once titration was complete, doses of medication, other than loop diuretics, had to be unchanged for 3 months before randomization. The methodology for radionuclide ventriculography (RNVG) used locally has been published in detail previously. 16 For each patient, the following was measured: LV end-diastolic volume in ml (LVEDV), LV end-systolic volume (LVESV [ml]), and LV ejection fraction (LVEF [%]). Baseline scans were conducted only once patients had been stabilized on maintenance doses of medication, including carvedilol, for at least 3 months. A second scan was performed at the end of the study. Statistical analysis Analyses were done using commercially available software (SPSS; SPSS, Chicago, IL). Data are reported as mean F 1 SD. Continuous variables between groups were compared by the Student t test for unpaired observations; multiple groups were compared using analysis of variance with Tukey analysis, where appropriate. Nominal data were compared by the m 2 with A and Cramer s V analysis. Power calculations were based on the within-patient difference between the baseline scan and the follow-up; 22 patients per group gave 90% power to detect a change in LVEDV of 30 ml. The excellent repeatability and reproducibility of the RNVG locally has previously been reported. 16 Results Screening of 307 patients attending the pacing clinic identified 87 patients who fulfilled the entry criteria, of whom 62 agreed to participate. All patients were stabilized on optimal doses of angiotensin-converting
3 American Heart Journal Volume 152, Number 4 Thackray et al. 713.e11 Figure 1 Graph showing the change in LV ejection fraction (%) and change in LVEDVs by gated RNVG for both pacing rate groups (high rate and low rate) from baseline to follow-up assessment ( represents the mean). enzyme inhibitor or angiotensin receptor blocker and spironolactone. Seven patients (11%) were intolerant of carvedilol and 6 (9%) patients withdrew during the 3-month up-titration period. Forty-nine patients were eventually randomized. Baseline characteristics were similar between groups (Table I). Mean age was 73 F 8 years; most were in New York Heart Association functional class III/IV, with ischemic heart disease, marked LV dilatation, and a depressed LV ejection fraction. The maintenance dose of carvedilol was 26 F 10 mg. Both groups were predominantly ventricular pacing dependent (high rate, 95% paced beats vs 92% for low rate, P = nonsignificant [NS]), leading to a mean 19-beat/min 1 difference in heart rate between the groups over the mean of 13.8 F 2.8 months of follow-up. Annualized mortality was 35%, and only 28 (58%) patients survived to the second assessment. Ten patients
4 713.e12 Thackray et al. American Heart Journal October 2006 died in each group; there was no excess mortality in patients with VVI pacemakers vs DDD pacemakers. The cause of death was worsening heart failure in 7 patients; sudden or unwitnessed death in 10; and stroke, cancer, and renal failure (1 each). No patient required or requested change in paced rate from that assigned. Three patients randomized to high-rate pacing had a technically inadequate baseline or follow-up scan. Of the patients completing the study (n = 25), in the high-rate group, 6 patients had a VVI pacemaker and 6, a DDD pacemaker; in the low-rate group, 6 had a VVI, and 7, a DDD pacemaker. Compared with higher-rate pacing, pacing at a lower rate was associated with reductions in mean end-systolic and end-diastolic volumes ( P =.006 and P =.03, respectively, for the difference between groups) and maintenance of LV ejection fraction ( P =.002 for the difference between groups). Of the 13 patients, 9 (69%) randomized to lower-rate pacing but only 1 (8%) of 12 randomized to higher-rate pacing showed an increase in ejection fraction and a reduction in LVEDV (m 2 = 57, P b.01) (Figure 1). Multivariable analysis showed no association between the improvement in LV function during long-term h-blockade and age, duration of pacing at entry, baseline LV function, type of pacemaker, or underlying rhythm. Discussion This study suggests that the benefits of h-blockade on LV volume and systolic function are attenuated or reversed by increasing the heart rate to a modest extent. This effect was independent of any other clinical or pacing parameter and sustained over a mean of N13 months of treatment. Clearly, heart rate is an important mediator of h-blocker effect, although this study does not preclude the possibility of additional benefit mediated via adrenergic receptor blockade. The small heart rate difference observed in the COMET study is unlikely to account for the substantial difference in mortality observed in that study. 6 The study is not of adequate design to test whether the observed changes in structure and function translate into a change in symptoms or prognosis. However, the study does confirm the dismal prognosis of patients with heart failure and conventional right ventricular pacing. It is possible that biventricular pacemakers should be used in such patients, and relevant trials are underway. 17 The DAVID trial 18 reported an increase in morbidity and mortality in patients with DDD back-up pacing. This effect is likely to have been mediated by an increase in desynchronising right ventricular pacing rather than an increase in average heart rate. The study is of considerable practical importance. Many patients with conventional pacemakers have or will develop heart failure, and biventricular pacing will be used increasingly. In both settings, the physician has the capacity to control ventricular rate and prevent bradycardia. This study provides evidence that the resting ventricular pacing rate should not be set high. Indeed, the smaller benefit observed in MUSTIC AF, 19 where patients had atrioventricular node ablation and backup pacing at 70 beat/min, compared with other trials of cardiac resynchronisation, lends further support to the concept that, when it comes to pacing, rate as well as synchrony matters in patients with LV systolic dysfunction. Limitations This is a small study with a high mortality rate during the study, reflecting the high mortality rate seen in patients with heart failure and pacemakers. Selecting patients with less profound degrees of cardiac impairment may have lead to a higher survival and, hence, follow-up rate for this study. Most patients became pacemaker-dependent during the study, either under the influence of h-blockade or a higher baseline pacing rate; this maximizes the opportunity to cause ventricular dysynchrony. We feel that both heart rate and ventricular dysynchrony are important issues in this patient group and the larger heart failure population. A larger study will be required to dissect out the relative contribution of these to the prognosis of these patients. A period of 9 months was allowed between baseline and follow-up scans to allow for reverse remodeling occurring under the influence of h-blockade. It was unexpected that during this period, such a large mortality rate would occur this represents a major flaw of the study. We thank Dr Michael Cooklin, Dr John Caplin, Dr Mike Norell, the regional cardiac physiologists and, in particular, the nuclear medicine radiographers for their support. References 1. Cleland JGF, Bristow M, Erdmann E, et al. Beta-blocking agents in heart failure: should they be used and how? Eur Heart J 1996;17: Doughty RN, Whalley GA, Gamble G, et al. On behalf of the Australia and New-Zealand heart failure research collaborative group: left ventricular remodelling with carvedilol in patients with congestive heart failure due to ischaemic heart disease. JACC 1997;29: Dubach P, Myers J, Bonetti P, et al. Effects of bisoprolol fumarate on left ventricular size, function, and exercise capacity in patients with heart failure: analysis with magnetic resonance myocardial tagging. Am Heart J 2002;143: Bristow MR, Ginsburg R, Minobe W, et al. Decreased catecholamine sensitivity and beta-adrenergic receptor density in failing human hearts. N Engl J Med 1982;307:
5 American Heart Journal Volume 152, Number 4 Thackray et al. 713.e13 5. Lowes BD, Gilbert EM, Abraham WT, et al. Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents. N Engl J Med 2002;346: Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003;362: Nagatsu M, Spinale FG, Koide M, et al. Bradycardia and the role of h-blockade in the amelioration of left ventricular dysfunction. Circulation 2000;101: Cice G, Tagliamonte E, Ferrara L, et al. Efficacy of carvedilol on complex ventricular arrhythmias in dilated cardiomyopathy: doubleblind, randomized, placebo-controlled study. Eur Heart J 2000; 21: Cleland JG, Pennell DJ, Ray SG, et al. Carvedilol hibernating reversible ischaemia trial: marker of success investigators. Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): randomised controlled trial. Lancet 2003;362: Jourdain P, Funck F, Fulla Y, et al. Myocardial contractile reserve under low doses of dobutamine and improvement of left ventricular ejection fraction with treatment by carvedilol. Eur J Heart Fail 2002;4: Waagstein F, Swedberg K, Hjalmarson A, et al. Improvement after metoprolol in idiopathic dilated cardiomyopathy is predicted by baseline systolic blood pressure and change in heart rate. JACC 1996;27 (Suppl A):170A. 12. Sackner-Bernstein JD, Lukas MA, Wu B. Evidence against heart rate reduction as the primary mechanism of carvedilol in chronic heart failure. JACC 1998;31:32a. 13. Lechat P, Hulot JS, Escolano S, et al. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial. Circulation 2001;103: Camm AJ, Lau CP. Electrophysiological effects of a single intravenous administration of ivabradine (s 16257) in adult patients with normal baseline electrophysiology. Drugs R D 2003;4: Thackray SD, Witte KK, Nikitin NP, et al. The prevalence of heart failure and asymptomatic left ventricular systolic dysfunction in a typical regional pacemaker population. Eur Heart J 2003;24: Wright GA, Thackray S, Howey S, et al. Left ventricular ejection fraction and volumes from gated blood-pool SPECT: comparison with planar gated blood-pool imaging and assessment of repeatability in patients with heart failure. J Nucl Med 2003;44: Cleland JG, Ghosh J, Khan NK, et al. Multi-chamber pacing: a perfect solution for cardiac mechanical dyssynchrony? Eur Heart J 2003;24: Wilkoff BL, Cook JR, Epstein AE, et al. Dual Chamber and VVI Implantable Defibrillator Trial Investigators Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial. JAMA 2002;288: Linde C, Leclercq C, Rex S, et al. Long-term benefits of biventricular pacing in congestive heart failure: results from the MUltisite STimulation in cardiomyopathy (MUSTIC) study. J Am Coll Cardiol 2002;40:111-8.
The Management of Heart Failure after Biventricular Pacing
The Management of Heart Failure after Biventricular Pacing Juan M. Aranda, Jr., MD University of Florida College of Medicine, Division of Cardiovascular Medicine, Gainesville, Florida Approximately 271,000
More informationThe benefit of treatment with -blockers in heart failure is
Heart Rate and Cardiac Rhythm Relationships With Bisoprolol Benefit in Chronic Heart Failure in CIBIS II Trial Philippe Lechat, MD, PhD; Jean-Sébastien Hulot, MD; Sylvie Escolano, MD, PhD; Alain Mallet,
More informationHeart Failure and Cardiomyopathy Center, Division of Cardiology, North Shore University Hospital, Manhasset, NY
NEUROHORMONAL ANTAGONISTS IN THE POST-MI PATIENT New Evidence from the CAPRICORN Trial: The Role of Carvedilol in High-Risk, Post Myocardial Infarction Patients Jonathan D. Sackner-Bernstein, MD, FACC
More informationEffects of heart rate reduction with ivabradine on left ventricular remodeling and function:
Systolic Heart failure treatment with the If inhibitor ivabradine Trial Effects of heart rate reduction with ivabradine on left ventricular remodeling and function: results of the SHIFT echocardiography
More informationIndications for and Prediction of Successful Responses of CRT for Patients with Heart Failure
Indications for and Prediction of Successful Responses of CRT for Patients with Heart Failure Edmund Keung, MD Clinical Chief, Cardiology Section San Francisco VAMC October 25, 2008 Presentation Outline
More informationEffects of heart rate reduction with ivabradine on left ventricular remodeling and function:
Systolic Heart failure treatment with the If inhibitor ivabradine Trial Effects of heart rate reduction with ivabradine on left ventricular remodeling and function: results of the SHIFT echocardiography
More informationEvidence Supporting Post-MI Use of
Addressing the Gap in the Management of Patients After Acute Myocardial Infarction: How Good Is the Evidence Supporting Current Treatment Guidelines? Michael B. Fowler, MB, FRCP Beta-adrenergic blocking
More informationEffect of Ventricular Pacing on Myocardial Function. Inha University Hospital Sung-Hee Shin
Effect of Ventricular Pacing on Myocardial Function Inha University Hospital Sung-Hee Shin Contents 1. The effect of right ventricular apical pacing 2. Strategies for physiologically optimal ventricular
More informationOptimal Adrenergic Blockades in Heart Failure. Jae-Joong Kim MD, PhD Asan Medical Center, University of Ulsan, Seoul, Korea
Optimal Adrenergic Blockades in Heart Failure Jae-Joong Kim MD, PhD Asan Medical Center, University of Ulsan, Seoul, Korea Contents Harmful effects of adrenergic system in heart failure Clinical studies
More informationJournal of the American College of Cardiology Vol. 37, No. 2, by the American College of Cardiology ISSN /01/$20.
Journal of the American College of Cardiology Vol. 37, No. 2, 2001 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.00 Published by Elsevier Science Inc. PII S0735-1097(00)01158-X Dilated
More informationLong-Term Outcome and Tolerability of Carvedilol Therapy in Japanese Patients With Chronic Heart Failure
Long-Term Outcome and Tolerability of Carvedilol Therapy in Japanese Patients With Chronic Heart Failure Naomi Naoki Yoko Yoshie Hiroshi KAWASHIRO, MD MATSUDA, MD ENDO, MD UCHIDA, MD KASANUKI, MD, FJCC
More informationESC Guidelines. ESC Guidelines Update For internal training purpose. European Heart Journal, doi: /eurheart/ehn309
ESC Guidelines Update 2008 ESC Guidelines Heart failure update 2008 For internal training purpose. 0 Agenda Introduction Classes of recommendations Level of evidence Treatment algorithm Changes to ESC
More informationCardiac Resynchronization Therapy: Improving Patient Selection and Outcomes
The Journal of Innovations in Cardiac Rhythm Management, 3 (2012), 899 904 DEVICE THERAPY CLINICAL DECISION MAKING Cardiac Resynchronization Therapy: Improving Patient Selection and Outcomes GURINDER S.
More informationArrhythmias and Heart Failure Dr Chris Lang Consultant Cardiologist and Electrophysiologist Royal Infirmary of Edinburgh
Arrhythmias and Heart Failure Dr Chris Lang Consultant Cardiologist and Electrophysiologist Royal Infirmary of Edinburgh Arrhythmias and Heart Failure Ventricular Supraventricular VT/VF Primary prevention
More informationDevice Therapy for Heart Failure
Device Therapy for Heart Failure Dr. Shelley Zieroth FRCPC Assistant Professor, Cardiology, University of Manitoba Director of Cardiac Transplant and Heart Failure Clinics St Boniface General Hospital,
More informationPROCORALAN MAKING A STRONG ENTRY TO THE NEW ESC GUIDELINES FOR THE MANAGEMENT OF HEART FAILURE
Press Release Issued on behalf of Servier Date: June 6, 2012 PROCORALAN MAKING A STRONG ENTRY TO THE NEW ESC GUIDELINES FOR THE MANAGEMENT OF HEART FAILURE The new ESC guidelines for the diagnosis and
More informationCase 1: A 54-year-old man with
CLINICIAN UPDATE -Blockers in Chronic Heart Failure Mihai Gheorghiade, MD; Wilson S. Colucci, MD; Karl Swedberg, MD Case 1: A 54-year-old man with a history of myocardial infarction (MI) presented with
More informationOnline Appendix (JACC )
Beta blockers in Heart Failure Collaborative Group Online Appendix (JACC013117-0413) Heart rate, heart rhythm and prognostic effect of beta-blockers in heart failure: individual-patient data meta-analysis
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Implantable cardioverter defibrillators for the treatment of arrhythmias and cardiac resynchronisation therapy for the treatment of heart failure (review
More informationDevices and Other Non- Pharmacologic Therapy in CHF. Angel R. Leon, MD FACC Division of Cardiology Emory University School of Medicine
Devices and Other Non- Pharmacologic Therapy in CHF Angel R. Leon, MD FACC Division of Cardiology Emory University School of Medicine Disclosure None University of Miami vs. OSU Renegade Miami football
More informationThoranis Chantrarat MD
Device Therapy in Heart Failure Thoranis Chantrarat MD 1 Scope of presentation Natural history of heart failure Primary and secondary prevention ICD and its indication CRT and its indication 2 Severity
More informationComparison of clinical trials evaluating cardiac resynchronization therapy in mild to moderate heart failure
HOT TOPIC Cardiology Journal 2010, Vol. 17, No. 6, pp. 543 548 Copyright 2010 Via Medica ISSN 1897 5593 Comparison of clinical trials evaluating cardiac resynchronization therapy in mild to moderate heart
More informationDobutamine-induced increase in heart rate is blunted by ivabradine treatment in patients with acutely decompensated heart failure
Dobutamine-induced increase in heart rate is blunted by ivabradine treatment in patients with acutely decompensated heart failure Yuksel Cavusoglu, KU Mert, A Nadir, F Mutlu, E Gencer, T Ulus, A Birdane
More informationPRESENTER DISCLOSURE INFORMATION. There are no potential conflicts of interest regarding current presentation
PRESENTER DISCLOSURE INFORMATION There are no potential conflicts of interest regarding current presentation Better synchrony and diastolic function for septal versus apical right ventricular permanent
More informationCKD Satellite Symposium
CKD Satellite Symposium Recommended Therapy by Heart Failure Stage AHA/ACC Task Force on Practice Guideline 2001 Natural History of Heart Failure Patients surviving % Mechanism of death Sudden death 40%
More informationBSH Annual Autumn Meeting 2017
BSH Annual Autumn Meeting 2017 Presentation title: The Development of CRT Speaker: John GF Cleland Conflicts of interest: I have received research support and honoraria from Biotronik, Boston Scientific,
More informationNational Horizon Scanning Centre. Irbesartan (Aprovel) for heart failure with preserved systolic function. August 2008
Irbesartan (Aprovel) for heart failure with preserved systolic function August 2008 This technology summary is based on information available at the time of research and a limited literature search. It
More informationAF in the ER: Common Scenarios CASE 1. Fast facts. Diagnosis. Management
AF in the ER: Common Scenarios Atrial fibrillation is a common problem with a wide spectrum of presentations. Below are five common emergency room scenarios and the management strategies for each. Evan
More informationBrian Olshansky, MD, FHRS,* John D. Day, MD, FHRS, Renee M. Sullivan, MD,* Patrick Yong, MSEE, Elizabeth Galle, MS, Jonathan S. Steinberg, MD, FHRS
Does cardiac resynchronization therapy provide unrecognized benefit in patients with prolonged PR intervals? The impact of restoring atrioventricular synchrony: An analysis from the COMPANION Trial Brian
More informationHeart Failure Medical and Surgical Treatment
Heart Failure Medical and Surgical Treatment Daniel S. Yip, M.D. Medical Director, Heart Failure and Transplantation Mayo Clinic Second Annual Lakeland Regional Health Cardiovascular Symposium February
More informationBi-Ventricular pacing after the most recent studies
Seminars of the Hellenic Working Groups February 18th-20 20,, 2010, Thessaloniki, Greece Bi-Ventricular pacing after the most recent studies Maurizio Lunati MD Director EP Lab & Unit Cardiology Dpt. Niguarda
More informationDiastolic Heart Failure. Edwin Tulloch-Reid MBBS FACC Consultant Cardiologist Heart Institute of the Caribbean December 2012
Diastolic Heart Failure Edwin Tulloch-Reid MBBS FACC Consultant Cardiologist Heart Institute of the Caribbean December 2012 Disclosures Have spoken for Merck, Sharpe and Dohme Sat on a physician advisory
More informationEHRA Accreditation Exam - Sample MCQs Cardiac Pacing and ICDs
EHRA Accreditation Exam - Sample MCQs Cardiac Pacing and ICDs Dear EHRA Member, Dear Colleague, As you know, the EHRA Accreditation Process is becoming increasingly recognised as an important step for
More informationMetoprolol CR/XL in Female Patients With Heart Failure
Metoprolol CR/XL in Female Patients With Heart Failure Analysis of the Experience in Metoprolol Extended-Release Randomized Intervention Trial in Heart Failure (MERIT-HF) Jalal K. Ghali, MD; Ileana L.
More informationHeart Failure in 2012 with reference to NICE Guidance Dr Maurice Pye Consultant Cardiologist York District Hospital
Heart Failure in 2012 with reference to NICE Guidance 2010 Dr Maurice Pye Consultant Cardiologist York District Hospital A little over elaborate,do not include ECG or CXR If clinical suspicion is high
More informationG Lin, R F Rea, S C Hammill, D L Hayes, P A Brady
Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USA Correspondence to: Dr Peter A Brady, MD, FRCP, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA; brady.peter@mayo.edu Accepted
More informationHEART FAILURE: PHARMACOTHERAPY UPDATE
HEART FAILURE: PHARMACOTHERAPY UPDATE 3 HEART FAILURE REVIEW 1 5.1 million x1.25 = 6.375 million 40 years old = MICHAEL F. AKERS, PHARM.D. CLINICAL PHARMACIST CENTRACARE HEALTH, ST. CLOUD HOSPITAL HF Diagnosis
More informationIs beta-blockade useful in heart failure patients with atrial fibrillation? An analysis of data from two previously completed prospective trials
The European Journal of Heart Failure 4 (2002) 489 494 Is beta-blockade useful in heart failure patients with atrial fibrillation? An analysis of data from two previously completed prospective trials Jeffrey
More information8:30-10:30 WS #4: Cardiology :00-13:00 WS #11: Cardiology 101 (Repeated)
Professor Ralph Stewart Cardiologist Auckland City Hospital Green Lane Cardiovascular Research Unit Auckland Heart Group Fiona Stewart Cardiologist Green Lane Hospital National Women's Hospital Professor
More informationRhythm Control: Is There a Role for the PCP? Blake Norris, MD, FACC BHHI Primary Care Symposium February 28, 2014
Rhythm Control: Is There a Role for the PCP? Blake Norris, MD, FACC BHHI Primary Care Symposium February 28, 2014 Financial disclosures Consultant Medtronic 3 reasons to evaluate and treat arrhythmias
More informationHeart Failure Update John Coyle, M.D.
Heart Failure Update 2011 John Coyle, M.D. Causes of Heart Failure Anderson,B.Am Heart J 1993;126:632-40 It It is now well-established that at least one-half of the patients presenting with symptoms and
More informationRate of Heart failure guideline adherence in a tertiary care center in India after accounting for the therapeutic contraindications.
Article ID: WMC004618 ISSN 2046-1690 Rate of Heart failure guideline adherence in a tertiary care center in India after accounting for the therapeutic contraindications. Peer review status: No Corresponding
More informationCarvedilol in Children With Cardiomyopathy: 3-Year Experience at a Single Institution
FAILING HEART MEDICAL ASPECTS Carvedilol in Children With Cardiomyopathy: 3-Year Experience at a Single Institution Paolo Rusconi, MD, a Orlando Gómez-Marín, MSc, PhD, a,b,c Marie Rossique-González, PharmD,
More informationTherapeutic Targets and Interventions
Therapeutic Targets and Interventions Ali Valika, MD, FACC Advanced Heart Failure and Pulmonary Hypertension Advocate Medical Group Midwest Heart Foundation Disclosures: 1. Novartis: Speaker Honorarium
More informationInnovation therapy in Heart Failure
Innovation therapy in Heart Failure P. Laothavorn September 2015 Topics of discussion Basic Knowledge about heart failure Standard therapy New emerging therapy References: standard Therapy in Heart Failure
More informationTopic Page: congestive heart failure
Topic Page: congestive heart failure Definition: congestive heart f ailure from Merriam-Webster's Collegiate(R) Dictionary (1930) : heart failure in which the heart is unable to maintain an adequate circulation
More informationCost effectiveness of beta blocker therapy for patients. with chronic severe heart failure. in Ireland. M. Barry
IMJ June 2002;95(6):174-177 Cost effectiveness of beta blocker therapy for patients with chronic severe heart failure in Ireland M. Barry Irish National Centre for Pharmacoeconomics Address for correspondence
More informationProphylactic pacemaker use to allow h-blocker therapy in patients with chronic heart failure with bradycardia
Congestive Heart Failure Prophylactic pacemaker use to allow h-blocker therapy in patients with chronic heart failure with bradycardia Eric C. Stecker, MD, MPH, a A. Mark Fendrick, MD, a Bradley P. Knight,
More informationPharmacological Treatment for Chronic Heart Failure. Dr Elaine Chau HK Sanatorium & Hospital, Hong Kong 3 August 2014
Pharmacological Treatment for Chronic Heart Failure Dr Elaine Chau HK Sanatorium & Hospital, Hong Kong 3 August 2014 1 ACC/AHA 2005 guideline update for Diagnosis & management of CHF in the Adult -SA Hunt
More informationPredictive Power of the Baseline QRS Complex Duration for Clinical Response to Cardiac Resynchronisation Therapy
CARDIAC RESYNCHRONISATION THERAPY ORIGINAL ARTICLE Predictive Power of the Baseline QRS Complex Duration for Clinical Response to Cardiac Resynchronisation Therapy Ali Kazemisaeid, MD, Ali Bozorgi, MD,
More informationManagement of Atrial Fibrillation in Heart Failure
Management of Atrial Fibrillation in Heart Failure Hani Sabbour MD FACC FHRS FASE Clinical Assistant Professor of Cardiology Brown University, Warren Alpert School of Medicine Rhode Island, USA Consultant
More informationThe new Guidelines: Focus on Chronic Heart Failure
The new Guidelines: Focus on Chronic Heart Failure Petros Nihoyannopoulos MD, FRCP, FESC Professor of Cardiology Imperial College London and National & Kapodistrian University of Athens 2 3 4 The principal
More informationJournal of the American College of Cardiology Vol. 52, No. 23, by the American College of Cardiology Foundation ISSN /08/$34.
Journal of the American College of Cardiology Vol. 52, No. 23, 2008 2008 by the American College of Cardiology Foundation ISSN 0735-1097/08/$34.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2008.08.027
More informationUpgrade to Resynchronization Therapy. Saeed Oraii MD, Cardiologist Interventional Electrophysiologist Tehran Arrhythmia Clinic May 2016
Upgrade to Resynchronization Therapy Saeed Oraii MD, Cardiologist Interventional Electrophysiologist Tehran Arrhythmia Clinic May 2016 Event Free Survival (%) CRT Cardiac resynchronization therapy (CRT)
More informationIHCP bulletin INDIANA HEALTH COVERAGE PROGRAMS BT JANUARY 24, 2012
IHCP bulletin INDIANA HEALTH COVERAGE PROGRAMS BT201203 JANUARY 24, 2012 The IHCP to reimburse implantable cardioverter defibrillators separately from outpatient implantation Effective March 1, 2012, the
More informationPredictive Power of the Baseline QRS Complex Duration for Clinical Response to Cardiac Resynchronisation Therapy
CARDIAC MARKERS ORIGINAL RESEARCH Predictive Power of the Baseline QRS Complex Duration for Clinical Response to Cardiac Resynchronisation Therapy Ali Kazemisaeid, MD, Ali Bozorgi, MD, Ahmad Yamini Sharif,
More informationState-of-the-Art Management of Chronic Systolic Heart Failure
State-of-the-Art Management of Chronic Systolic Heart Failure Michael McCulloch, MD 17 th Annual Cardiovascular Update Intermountain Medical Center December 16, 2017 Disclosures: I have no financial disclosures
More informationJournal of the American College of Cardiology Vol. 50, No. 13, by the American College of Cardiology Foundation ISSN /07/$32.
Journal of the American College of Cardiology Vol. 50, No. 13, 2007 2007 by the American College of Cardiology Foundation ISSN 0735-1097/07/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2007.04.096
More informationNew Agents for Heart Failure: Ivabradine Jeffrey S. Borer, MD
New Agents for Heart Failure: Ivabradine Jeffrey S. Borer, MD Professor of Medicine, Cell Biology, Radiology and Surgery Director, The Howard Gilman Institute for Heart Valve Disease and the Schiavone
More information'Understanding Atrial Fibrillation: New Insights in Pathophysiology
82 nd Annual Scientific Meeting of the Japanese Circulation Society Osaka 2018 'Understanding Atrial Fibrillation: New Insights in Pathophysiology Barbara Casadei, MD DPhil FMedSci FESC British Heart Foundation
More informationManagement of ATRIAL FIBRILLATION. in general practice. 22 BPJ Issue 39
Management of ATRIAL FIBRILLATION in general practice 22 BPJ Issue 39 What is atrial fibrillation? Atrial fibrillation (AF) is the most common cardiac arrhythmia encountered in primary care. It is often
More informationChecklist for Treating Heart Failure. Alan M. Kaneshige MD, FACC, FASE Oklahoma Heart Institute
Checklist for Treating Heart Failure Alan M. Kaneshige MD, FACC, FASE Oklahoma Heart Institute Novartis Disclosure Heart Failure (HF) a complex clinical syndrome that arises secondary to abnormalities
More informationHeart Failure. GP Update Refresher 18 th January 2018
GP Update Refresher 18 th January 2018 Heart Failure Dr. Alexander Lyon Senior Lecturer and Consultant Cardiologist Clinical Lead in Cardio-Oncology Royal Brompton Hospital, London UK President of British
More informationSummary, conclusions and future perspectives
Summary, conclusions and future perspectives Summary The general introduction (Chapter 1) of this thesis describes aspects of sudden cardiac death (SCD), ventricular arrhythmias, substrates for ventricular
More informationCardiac Resynchronization Therapy for Heart Failure
Cardiac Resynchronization Therapy for Heart Failure Ventricular Dyssynchrony vs Resynchronization Ventricular Dysynchrony Ventricular Dysynchrony 1 Electrical: Inter- or Intraventricular conduction delays
More informationPolypharmacy - arrhythmic risks in patients with heart failure
Influencing sudden cardiac death by pharmacotherapy Polypharmacy - arrhythmic risks in patients with heart failure Professor Dan Atar Head, Dept. of Cardiology Oslo University Hospital Ullevål Norway 27.8.2012
More informationWhat s new in heart failure management? Yonsei Cardiovascular Center Yonsei University College of Medicine
What s new in heart failure management? Yonsei Cardiovascular Center Yonsei University College of Medicine Current Guideline of Treatment Asymptomatic Mild/Mod Severe Refractory Correct Cause: Arrhythmias
More informationEvaluation of Ejection Fraction in Patients with Cardiac Resynchronization Therapy by Two and Three Dimensional Echocardiography
58 Original article Evaluation of Ejection Fraction in Patients with Cardiac Resynchronization Therapy by Two and Three Dimensional Echocardiography Anil OM Department of cardiology, Manmohan Cardiothoracic
More informationBeta-Blockade in Heart Failure A Comparison of Carvedilol With Metoprolol
Journal of the American College of Cardiology Vol. 34, No. 5, 1999 1999 by the American College of Cardiology ISSN 0735-1097/99/$20.00 Published by Elsevier Science Inc. PII S0735-1097(99)00367-8 A Comparison
More informationLeft Ventricular Ejection Fraction >35%
Controversies in Cardiac Resynchronisation Therapy Left Ventricular Ejection Fraction >35% Professor John GF Cleland University of Hull Kingston-upon-Hull United Kingdom Conflict of Interest: I have received
More informationESC Guidelines for the Diagnosis and Treatment of Chronic Heart Failure
ESC Guidelines for the Diagnosis and Treatment of Chronic Heart Failure - 2005 Karl Swedberg Professor of Medicine Department of Medicine Sahlgrenska University Hospital/Östra Göteborg University Göteborg
More informationAtrial fibrillation (AF) is a disorder seen
This Just In... An Update on Arrhythmia What do recent studies reveal about arrhythmia? In this article, the authors provide an update on atrial fibrillation and ventricular arrhythmia. Beth L. Abramson,
More informationDo All Patients With An ICD Indication Need A BiV Pacing Device?
Do All Patients With An ICD Indication Need A BiV Pacing Device? Muhammad A. Hammouda, MD Electrophysiology Laboratory Department of Critical Care Medicine Cairo University Etiology and Pathophysiology
More informationSliwa et al. JACC 2004;44:
TREATMENT OF ADVANCED HEART FAILURE HEART DISEASE IN KENTUCKY Navin Rajagopalan, MD Assistant Professor of Medicine University of Kentucky Director, Congestive Heart Failure Medical Director of Cardiac
More informationCarvedilol Increases Two-Year Survival in Dialysis Patients With Dilated Cardiomyopathy A Prospective, Placebo-Controlled Trial
Journal of the American College of Cardiology Vol. 41, No. 9, 2003 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Inc. doi:10.1016/s0735-1097(03)00241-9
More informationDefinition of Congestive Heart Failure
Heart Failure Definition of Congestive Heart Failure A clinical syndrome of signs & symptoms resulting from the heart s inability to supply adequate tissue perfusion. CHF Epidemiology Affects 4.7 million
More informationHeart Failure Management. Waleed AlHabeeb, MD, MHA Assistant Professor of Medicine Consultant Heart Failure Cardiologist
Heart Failure Management Waleed AlHabeeb, MD, MHA Assistant Professor of Medicine Consultant Heart Failure Cardiologist Heart failure prevalence is expected to continue to increase¹ 21 MILLION ADULTS WORLDWIDE
More informationHeart Failure Treatments
Heart Failure Treatments Past & Present www.philippelefevre.com Background Background Chronic heart failure Drugs Mechanical Electrical Background Chronic heart failure Drugs Mechanical Electrical Sudden
More informationJournal of the American College of Cardiology Vol. 37, No. 3, by the American College of Cardiology ISSN /01/$20.
Journal of the American College of Cardiology Vol. 37, No. 3, 2001 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.00 Published by Elsevier Science Inc. PII S0735-1097(00)01162-1 Left
More informationAF Today: W. For the majority of patients with atrial. are the Options? Chris Case
AF Today: W hat are the Options? Management strategies for patients with atrial fibrillation should depend on the individual patient. Treatment with medications seems adequate for most patients with atrial
More informationCardiac Resynchronisation Therapy for all Patients Requiring Ventricular Pacing
Cardiac Resynchronisation Therapy for all Patients Requiring Ventricular Pacing Philippe Mabo University Hospital, Rennes, France ESC Congress 2010, Stockholm 29 Aug 2010 Which Patients? Candidate for
More informationDialysis-Dependent Cardiomyopathy Patients Demonstrate Poor Survival Despite Reverse Remodeling With Cardiac Resynchronization Therapy
Dialysis-Dependent Cardiomyopathy Patients Demonstrate Poor Survival Despite Reverse Remodeling With Cardiac Resynchronization Therapy Evan Adelstein, MD, FHRS John Gorcsan III, MD Samir Saba, MD, FHRS
More informationHeart Failure Management Update
Heart Failure Management Update Rafique Ahmed, MD, PhD, FACC, FCPS Consultant Cardiac Electrophysiologist Baltimore, Maryland, USA Heart Failure - Definition The situation when the heart is incapable of
More informationCT Academy of Family Physicians Scientific Symposium October 2012 Amit Pursnani, MD
CT Academy of Family Physicians Scientific Symposium October 2012 Amit Pursnani, MD Clinical syndrome resulting from a structural or functional cardiac disorder that impairs the ability of the heart to
More informationModule 1: Evidence-based Education for Health Care Professionals
Module 1: Evidence-based Education for Health Care Professionals Heart Failure is a HUGE Problem Prevalence Incidence Mortality Hospital Discharges Cost 1 5,300,000 660,000 284,965 1,084,000 $34.8 billion
More informationBeta-Blocker Therapy and Severe Heart Failure: Myth or Reality?
BETA BLOCKERS AND HF CHF JULY/AUGUST 2003 197 Beta-Blocker Therapy and Severe Heart Failure: Myth or Reality? The medical management of heart failure has undergone remarkable progress in the past 10 years.
More informationUnderstanding and Development of New Therapies for Heart Failure - Lessons from Recent Clinical Trials -
Understanding and Development of New Therapies for Heart Failure - Lessons from Recent Clinical Trials - Clinical trials Evidence-based medicine, clinical practice Impact upon Understanding pathophysiology
More informationJournal of the American College of Cardiology Vol. 33, No. 4, by the American College of Cardiology ISSN /99/$20.
Journal of the American College of Cardiology Vol. 33, No. 4, 1999 1999 by the American College of Cardiology ISSN 0735-1097/99/$20.00 Published by Elsevier Science Inc. PII S0735-1097(98)00675-5 Beta-Adrenergic
More informationHeart Failure (HF) Treatment
Heart Failure (HF) Treatment Heart Failure (HF) Complex, progressive disorder. The heart is unable to pump sufficient blood to meet the needs of the body. Its cardinal symptoms are dyspnea, fatigue, and
More informationLong-Term Prognosis After Cardiac Resynchronization Therapy Is Related to the Extent of Left Ventricular Reverse Remodeling at Midterm Follow-Up
Journal of the American College of Cardiology Vol. 53, No. 6, 29 29 by the American College of Cardiology Foundation ISSN 735-97/9/$36. Published by Elsevier Inc. doi:.6/j.jacc.28..32 Cardiac Resynchronization
More informationIMPLANTABLE DEVICE THERAPY FOR HEART FAILURE
IMPLANTABLE DEVICE THERAPY FOR HEART FAILURE Nora Goldschlager, M.D. MACP, FACC, FAHA, FHRS Cardiology San Francisco General Hospital UCSF Disclosures: None LEADING CAUSES OF DEATH IN US Sudden cardiac
More informationThe Failing Heart in Primary Care
The Failing Heart in Primary Care Hamid Ikram How fares the Heart Failure Epidemic? 4357 patients, 57% women, mean age 74 years HFSA 2010 Practice Guideline (3.1) Heart Failure Prevention A careful and
More informationCarlo Budano. Closed loop physiological stimulation: from the pacemaker patient to the patient with an ICD
Closed loop physiological stimulation: from the pacemaker patient to the patient with an ICD Carlo Budano Dipartimento Cardiovascolare Città della Salute e della Scienza di Torino Physiological rate regulation
More informationMake you feel better Make you live longer
Drugs and Devices for Women with Heart Disease Sharonne N. Hayes MD, FACC Director, Women s Heart Clinic Mayo Clinic Rochester, MN CP986192-1 CP1045209-2 Goals of Medical Treatments for Heart Disease Make
More informationIncidence. 4.8 million in the United States. 400,000 new cases/year. 20 million patients with asymptomatic LV dysfunction
Heart Failure Diagnosis According to the Working Group in Heart Failure, CHF is a syndrome where the diagnosis has the following essential components: A combination of: Symptoms, typically breathlessness
More informationNeed to Know: Implantable Devices. Carolyn Brown RN, MN, CCRN Education Coordinator Emory Healthcare Atlanta, Georgia
Need to Know: Implantable Devices Carolyn Brown RN, MN, CCRN Education Coordinator Emory Healthcare Atlanta, Georgia Disclosure Statement I have no relationships to disclose. Objectives Discuss the most
More informationHeart Failure with preserved ejection fraction (HFpEF)
Heart Failure with preserved ejection fraction (HFpEF) Dr. Pierpaolo Pellicori Hull York Medical School Kingston-upon-Hull United Kingdom Conflict of interest: none Heart failure is a contemporary problem
More informationModule 1: Evidence-based Education for Health Care Professionals
Module 1: Evidence-based Education for Health Care Professionals Heart Failure is a HUGE Problem Prevalence Incidence Mortality Hospital Discharges Cost 1 5,300,000 660,000 284,965 1,084,000 $34.8 billion
More informationA patient with decompensated HF
A patient with decompensated HF Professor Michel KOMAJDA University Pierre & Marie Curie Pitie Salpetriere Hospital Department of Cardiology Paris (France) Declaration Of Interest 2010 Speaker : Servier,
More information